Changes in platelet CD 62P expression and soluble P-selectin concentration in surgically treated colorectal carcinoma

The aim of the present study was to assess the effect of tumor advancement and surgery treatment on P-selectin expression (CD 62P), level of sP-selectin and platelet count.

The study involved 27 colorectal cancer patients (CRC). They were divided into two groups: group B1--18 patients (T2-3N0M0) and group B2--9 patients (T2-4N+M0). In CRC patients the blood was collected three times: 1) before surgery (A0), 2) 3 days after surgery and 3) 12 days after surgery.

The results obtained showed that CD 62P expression in CRC patients was twice higher (5.36%) than in control (2.58%) (p < 0.001). The level of sP-selectin concentration in both groups (B1--74.22 ng/mL and B2--70.33 ng/mL) was significantly higher than in control (46.01 ng/mL) (p < 0.001). There was no significant differences in CD 62P expression, plasma sP-selectin concentration and in PLT count between group B1 and B2. Three days after surgery in both groups of patients we observed decreased CD 62P expression and sP-selectin level compared to the results before surgery (p < 0.05). Twelve days after surgery we found an increase in the CD 62P-positive platelets and sP-selectin in group B1 and B2. We found positive correlation between plasma sP-selectin concentration and PLT count in CRC.

In the current study on colorectal cancer we observed platelet hyperactivation, irrespective of tumor clinical advancement. Surgical procedure, in the early period following radical tumor resection, does not totally eliminate platelet activation in vivo.